Sage Journals: Discover world-class research

Abstract

Pulmonary arterial hypertension (PAH) is a unique disease. Properly speaking, it is not a disease of the lung. It can be seen more as a microvascular disease occurring mainly in the lungs and affecting the heart. At the cellular level, the PAH paradigm is characterized by inflammation, vascular tone imbalance, pulmonary arterial smooth muscle cell proliferation and resistance to apoptosis and the presence of in situ thrombosis. At a clinical level, the aforementioned abnormal vascular properties alter physically the pulmonary circulation and ventilation, which greatly influence the right ventricle function as it highly correlates with disease severity. Consequently, right heart failure remains the principal cause of death within this cohort of patients. While current treatment modestly improve patients' conditions, none of them are curative and, as of today, new therapies are lacking. However, the future holds potential new therapies that might have positive influence on the quality of life of the patient. This article will first review the clinical presentation of the disease and the different molecular pathways implicated in the pathobiology of PAH. The second part will review tomorrow's future putative therapies for PAH.

Keywords

pulmonary arterial hypertension micro-ribonucleic acid remodeling pathways vascular tone imbalance future therapies

Pulmonary arterial hypertension (PAH) is a severe disease characterized by a progressive increase of pulmonary vascular resistance due to various degrees of adventitia, media, and intima remodeling of the distal pulmonary arteries. This phenotype has been attributed to an increase in pulmonary artery smooth muscle cells (PASMCs) proliferation and resistance to apoptosis.^[1] Data from a recent epidemiological study show that 20–50 persons per million suffer from PAH.^[23] The underlying causes of PAH were revised during the World Symposium on Pulmonary Hypertension (PH] held in Dana Point, California, USA in 2008. Table 1 presents the groups and subgroups of pulmonary hypertension. The clinical definition of PAH includes a mean pulmonary arterial pressure (mPAP) greater than 25 mmHg at rest, but it also includes extended parameters such as a left atrial pressure, estimated by the pulmonary capillary wedge pressure (PAWP), of 15 mmHg or less.^[4] Nonetheless, lack of specific symptoms often leads to a late diagnosis and a worsening of the prognostic.^[5] Therapies are limited, not curative, and PAH remains associated with a poor long-term prognosis.^[6] The first part of this review will focus on the latest concepts explaining the PASMCs proliferative- and apoptosis-resistant phenotype that contributes to distal pulmonary artery remodeling in PAH, while the second part will discuss tomorrow's future putative therapies for PAH.

Table 1:

Updated clinical classification of pulmonary hypertension Dana Point, 2008

Pulmonary arterial hypertension (PAH)

Idiopathic

Heritable

BMPR2

ALK1, endoglin (with or without hereditary hemorrhagic telangiectasia)

Unknown

Drug- and toxin-induced

Associated with

Connective tissue diseases

Congenital systemic-to-pulmonary shunts

Portal hypertension

HIV infection

Schistosomiasis

Chronic hemolytic anemia

Persistent pulmonary hypertension of the newborn

Pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)

Pulmonary hypertension with left heart disease

Systolic dysfunction

Diastolic dysfunction

Valvular disease

Pulmonary hypertension associated with lung disease and/or hypoxemia

Chronic obstructive pulmonary disease

Interstitial lung disease

Other pulmonary diseases with mixed restrictive and obstructive pattern

Sleep-disordered breathing

Alveolar hypoventilation disorders

Chronic exposure to high altitude

Developmental abnormalities

Chronic thromboembolic pulmonary hypertension (CTEPH)

Pulmonary hypertension with unclear multifactorial mechanisms

Hematologic disorders: Myeloproliferative disorders, splenectomy

Systemic disorders: Sarcoidosis, pulmonary Langerhans cell histiocytosis: Lymphangioleiomyomatosis, neurofibromatosis, vasculitis

Metabolic disorders: Glycogen storage disease, Gaucher disease, thyroid disorders

Others: Tumoral obstruction, fibrosing mediastinitis, chronic renal failure on dialysis

Adapted from “Updated clinical classification of pulmonary hypertension,” by G. Simonneau et al., 2009, Journal of the American College of Cardiology, 54 (1 Suppl), p. S43–54. © 2009 by the American College of Cardiology Foundation Adapted with permission

CLINICAL AND FUNDAMENTAL MANIFESTATIONS OF PAH

Abnormal pulmonary circulation

The normal pulmonary circulation works on high blood flow volume, low-pressure system, and low-resistance regulation. Pulmonary vasodilatation and vasoconstriction balance are important mechanisms that modulate PVR to adapt to changes such as an increase in cardiac output (CO), resulting in a minimal increase in mPAP. To maintain this tightly balanced regulation, the healthy pulmonary vasculature presents many differences compared to systemic vasculature composition. The pulmonary arteries' and arterioles' walls are thinner, and their smooth muscular tones lower than those of the systemic vasculature. Structural changes occur in PAH, such as sustained vasoconstriction, abnormal vascular remodeling with an increase in the size (hypertrophy) and number (hyperplasia) of the smooth muscle cells in the media, and the adventitia of peripheral precapillary pulmonary arteries. The unique plexiform lesions formed by endothelial cells (ECs) lead finally to the obliteration of the arterioles and capillaries.^[7–10] The presence of a sustained hypoxic state can be a factor which enhances pulmonary vasoconstriction and leads to pulmonary vascular medial hypertrophy. The combination of those pathological features lead to decreased gas exchange efficiency.^[10–12] The mPAP is a function of CO and PVR, as illustrated by mPAP = CO × PVR + PAWP. PVR is inversely related to arterial lumen radius (r) (PVR α 1 / r⁴), as illustrated in Figure 1. Thus, the PVR can be significantly influenced by only small changes in the intra-luminal radius. Although large and small pulmonary arteries can influence the PVR, structural changes in small arterioles contribute to a more important variation in the PVR when compared to changes in the larger pulmonary arteries, as seen in animals and patients suffering from PAH.^[10]

Figure 1:

Determinant of abnormal mPAP in PAH. The lumen in control's rat lung allows normal PVR as the artery shows no signs of remodeling. Hence, the mPAP is normal. In the presence of a reduced radius, an increased in the PVR is observed. The function illustrates that only a small change in the radius is needed to elevate the PVR. Therefore, even with a normal CO, the mPAP will be elevated. mPAP = mean pulmonary arterial pressure; r = radius; PVR = pulmonary vascular resistance; CO = cardiac output; PAWP = pulmonary arterial wedge pressure.

Abnormal right ventricular function

The progressive narrowing of the pulmonary microvascular bed, the imbalance between vasodilatation and vasoconstriction, and the presence of in situ thrombosis lead to an increased PVR and mPAP which directly impact the right ventricle (RV). As the RV function declines, a circle of events slowly progress to finally lead to RV failure.^[13]

The RV has greater compliance than the left ventricle due to his anatomical particularities, including a thinner wall structure and a crescent shape.^[14] The first change due to PAH in RV function is an increase in its afterload, directly related to the increase in PVR and the decrease in pulmonary vascular compliance.^[15] The rising systolic, and the following rising diastolic, pressures increase the shear stress applied on the RV wall. Initially, this additional mechanic stress leads to an increase in myocardial mass through an increase in protein synthesis and an increase in cardiomyocyte size by the addition of sarcomere. Therefore, an adaptive RV hypertrophy occurs. In the event of a constant pressure overload, it eventually transits to dilatation. Those changes are well sustained when occurring in the left ventricle, but not in the RV, and the transition toward dilatation/failure occurs much earlier. Although not well understood, evidence shows that it could originate from an imbalance between the oxygen demand and supply in the cardiomyocyte.

Taken together, the increased wall tension and decreased myocardial perfusions progressively lead to a further decreased contractility and dilatation of the RV. As RV function decreases, the increase in RV contraction time and asynchrony leads to a decreased RV stroke volume and by extension to an underfilling of the left ventricle, especially during early diastole.^[16–18] The left ventricle filling is also impaired by the progressive development of leftward ventricular septal bowing.^[16,17,19] Taken all together, the impaired systolic and diastolic RV function combined with increased mechanical pressure and progressive left ventricle impairment are major components of the reduced cardiac output seen in severe PAH.

SIGNAL INITIATION: CIRCULATING FACTORS

Growth factors

Many growth factors have been identified to play an important role in PAH. When they bind and activate transmembrane cell surface receptor tyrosine kinases (RTKs), they act as potent chemo attractants for cells implicated in PAH pathogenesis like smooth muscle cells, fibroblasts, and ECs.^[20]

Vascular endothelial growth factor (VEGF). VEGF has a prosurvival and antiapoptotic role in ECs.^[21] Its biological effect is regulated by two RTKs (VEGFR1, VEGFR2).^[22] High levels of VEGF^[23] and VEGF receptor-2 expressions^[24–26] have been observed in PAH patients' lung samples. VEGF and VEGFR2 are expressed by ECs within the plexiform lesions in lungs from patients with PAH.^[25,27] Therefore, this angioproliferative growth factor and its receptor have a direct implication in PAH. Short- and long-term exposure to hypoxia upregulates VEGF gene and protein expressions.^[28] However, in the monocrotaline (MCT) rat model of PAH, causing an early event of endothelial injury, VEGF expression seems to be decreased.^[29] Therefore, VEGF overexpression protects against chronic hypoxia and MCT exposure.^[28] A model of severe PAH, caused by inhibition of VEGFR2 expression through SU5416 injection and followed by exposure to chronic hypoxia, has been recently developed. The VEGFR blockade has been shown to cause initial EC apoptosis, followed by the selection of EC clone resistant to apoptosis which, by proliferating, will form severe angio-obliterative lesions contributing to PAH and a right heart failure after exposure to hypoxia.^[30]

Platelet-derived growth factor (PDGF) and epidermal growth factor (EGF). Platelet-derived growth factor (PDGF) expression is found in many cell types, including ECs and smooth muscle cells in PAH. It promotes cellular proliferation, migration, survival, and transformation through the activation of two PDGF receptors (PDGFRα and PDGFRβ of RTK family). The expression of PDGF and PDGFR is increased in distal pulmonary arteries of patients with PAH.^[31–33] Of particular interest, Schermuly et al. found that PDGFR antagonists effectively treat severe PAH in MCT rats and hypoxic mice by reducing pulmonary remodeling, right heart hypertrophy, and improving CO.^[32] Therefore, the inhibition of the PDGFR signalization becomes a potential target to inhibit cellular abnormal proliferation, survival, and migration. Several drugs targeting the PDGFR have been recently investigated in clinical studies with encouraging results.^[34,35] A recent study digs the implication of PDGF in cellular proliferation a little deeper. They highlighted the implication PDGF and PDGFR in the Akt/mTor signaling pathway that leads to increased expression of both the stromal interacting molecule (STIMI), a sensor detecting a Ca²⁺ decrease in the SR/ER membrane, and Orail, a pore forming channel protein in the plasma membrane implicated in the upregulation of the store-operated Ca²⁺ entry (SO CE), a subsequent rise in the intracellular Ca²⁺ concentration ([Ca²⁺].), and resulting in the promotion of PASMC proliferation and tone.^[36] Also, Ciuclan et al. proposed a link between PDGFR-β phosphorylation and subsequent enhancement of tryptophan hydroxylase 1 (TPH1) in PAH. Indeed, a hypoxia-dependent TPH1 expression has been showed diminished by administration of PDGFR antagonist.^[37] Those new data deepen our knowledge concerning the action of PDGF inhibitors.

The epidermal growth factor (EGF) family had generated a growing interest in PAH. The EGFR/ErbB family includes four receptors, namely the HER1/EGFR (ErbB1), HER/2neu (ErbB2), HER3 (ErbB3), and HER4 (ErbB4). EGFR/ErbB belongs to the RTK family and is highly investigated in many human cancers and the target of several anticancer therapies.^[38] An increased EGFR signaling has been associated with EGF-related smooth muscle proliferation and the development of PAH in mice over-expressing TGF-α.^[39,40] Thus, the inhibition of EGFR has been thought to be therapeutically interesting. However, the inhibition of this signal only had partial efficacy in MCT rodent models and no significant efficacy on EGFR expression in the lungs of PAH patients.^[41]

Pro-inflammatory molecules

The presence of inflammation is commonly observed in the pathological presentation of PAH. In addition, patients with systemic inflammation condition, found in scleroderma or systemic lupus erythematosus, can develop PAH, and generally a more severe form of PAH. Cytokine and chemokine-dependent mechanisms leading to inflammatory cell recruitment are prominent in PAH.^[42] Pulmonary vessel infiltration by inflammatory cells like dendritic cells, T and B lymphocytes, and macrophages, as well as increased plasmatic concentrations of interleukin (IL)-1 and IL-6 have been reported in human and experimental PAH, suggesting that inflammation is implicated in the pathophysiology of PAH.^[43] Perivascular and interstitial inflammatory infiltrates are predominantly composed of mononuclear cells, mainly lymphocytes, with a minority of macrophages and neutrophils.^[27,44] Also, CD44, a cell adhesion molecule, is over expressed in pulmonary artery ECs within plexiform lesions and surrounded by T-cell infiltrates in PAH patients.^[45] Recently, the work of Ormiston and colleagues has identified an impairment of natural killer (NK) cells in iPAH, HPAH, and in two widely used animal models.^[46] In patients, abnormal NK cell phenotype was marked by a rise in the functionally deficient CD56⁻/CD16⁺ subset, not observed in the control group. In animal models, reduction in NK cell number, cytolytic activity, and cytokine production were demonstrated. The innate immunity seems, therefore, to be altered and might play a role in the pathobiology of the disease.

Vascular tone mediators imbalance

ECs produce endothelin, a member of the 21-amino acid peptides family and known to play an important role in vascular tone regulation. Endothelial dysfunctions are observed in PAH, and they lead to a reduced production of vasodilatory mediators.^[47,48] In fact, Endothelin-1 (ET-1) expression is increased in PAH compared to healthy subjects, enhancing an increase in intracellular calcium and activating the protein kinase C and resulting in a vasoconstriction of the smooth muscle cells through ET_B receptors.^[49] Endothelin expression is stimulated by cytokines, catecholamine, or substances from platelet-derived aggregation and can be downregulated by prostaglandins, nitric oxide (NO), and oxidant stress.^[50] Moreover, plasma levels of circulating ET-1 correlate with PAH severity.^[51] Prostaglandin I₂ (prostacyclin) is a strong endogenous vasodilator that increases the activation of cyclic adenosine monophosphate (cAMP) and by this process induces smooth muscle cell relaxation.^[52] Additionally, prostacyclin (PGI₂) inhibits platelet aggregation and smooth muscle cell proliferation. Prostacyclin is produced in the vascular endothelium using arachidonic acid as a precursor. Prostacyclin production is deficient in ECs of patients with PAH. Indeed, levels of PGI₂ metabolites are lower in the urine of PAH patients.^[48] Moreover, a decreased production of prostacyclin synthase is seen in PAH small and medium pulmonary arteries.^[53] This impaired production of PGI₂ leads to vascular tone imbalance and even pulmonary remodeling.

The NO diffuses through vascular smooth muscle cells to convert guanosine triphosphate (GTP) into cyclic guanosine monophosphate (cGMP)^[54] that initiates a cascade of reactions that ultimately lead to decreased intracellular calcium ([Ca²⁺].) level and vascular smooth muscle cell relaxation.^[55,56] Thus, the endothelium dependent vasodilatation, relayed by NO, is reduced in hypoxia-induced PAH in rats^[57] as well as in human alveolar hypoxia-induced PAH^[58–61] and Eisenmenger syndrome-induced PAH.^[62] The cGMP concentration also depends on the fifth isoform of the phosphodiesterase (PDE-5) that converts cGMP into GMP, which do not have any effects on vasodilatation.^[63] Therefore, reduced NO and cGMP concentrations cannot effectively counterbalance the levels of vasoconstrictive mediators thromboxane and ET-1 that are increased in PAH.^[47,48] An elevated plasmatic concentration of serotonin has been identified in severe PAH patients suggesting enhanced serotonin production, transport, and paracrine activity near PASMCs.^[64,65] Furthermore, even after heart-lung, single-lung, or double-lung transplantation (the only current way to cure PAH^[66]), plasma serotonin concentrations remain increased.^[67] Therefore, this persistent abnormality suggests that it originates prior to the development of PAH.

Ions imbalance

Pulmonary vasculature tone is regulated by an important mechanism, the hypoxic pulmonary vasoconstriction (HPV). It is a physiological response of the small pulmonary arteries that diverts deoxygenated blood away from hypoxic alveoli, thus optimizing the matching perfusion and ventilation and preventing arterial hypoxia. Exposition of PASMCs to chronic hypoxia and elevated ET-1 induce structural changes in pulmonary arteries and increase pulmonary vascular tone. Chronic hypoxia reduces the voltage-gated K⁺ channel (Kv channel) and the two-pore domain K⁺ channel (K_2p) currents, impairs HPV, and reduces O₂-sensitive K⁺ current,^[68,69] leading to PASMC membrane depolarization thereby promoting cell growth and migration.^[68] More specifically, the sensitivity of K_2p channels regulates vascular tone, particularly in small pulmonary vessels.^[70–72] The TWIK-related acid sensitive K⁺ channel K_2p 3.1 (TASK1) influences greatly the resting membrane potential in human PASMCs and has been demonstrated to be inhibited by ET-1 in PAH.^[72,73] Recently, it has been demonstrated that TASK1 channel inhibition by ET-1 is RhoA and Rho kinase dependent, which contributes to PAH at a molecular level.^[74] Also, chronic hypoxia is associated with a decreased expression in messenger ribonucleic acid (mRNA) levels of Kv1.1, Kv1.5, Kv2.1, Kv4.3, and Kv9.3 α-subunits in cultured rat PASMCs.^[75–77] Taken together, the change in the Kv and K_2p channel currents and the deceased expression of the Kv channels reduce the K⁺ trans-membrane influx and lead to depolarization.

The increased intracellular calcium ion concentration ([Ca²⁺].) plays an important role in pulmonary vascular constriction. Chronic hypoxia causes an increased ET-1-mediated vasoconstriction through downregulation of Kv channels, but also an upregulation of the canonical transient receptor potential (TRPC) channel expression, resulting in PASMCs' membrane depolarization and activation of the voltage-operated L-type Ca²⁺ channels (VOCC), leading to an increased Ca²⁺ influx.^[78,79] In addition, ET-1 increases the sensitivity to Ca²⁺ in the PASMCs.^[80] [Ca²⁺]_i is also increased through voltage independent pathways involving the store-operated Ca²⁺ channels (SOC) activated by intracellular depletion of Ca²⁺, and the receptor-operated Ca²⁺ channels (ROC) activated by interaction of an agonist with a membrane receptor.^[81,82] Exposition to chronic hypoxia has been demonstrated to activate the Ca²⁺-dependant transcription factor Nuclear factor of activated T cells (NEAT) in vitro and in vivo.^[83] Increased [Ca²⁺]_i leads to calcineurin activation, which dephosphorylates NFAT and exposes nuclear localization signal that allows NFAT nuclear translocation.^[78] Also of interest, the calcium-sensitive potassium channels (BK_Ca) conduct ionic currents that mediate membrane hyperpolarization and vascular relaxation, and their activities are regulated by membrane potential (Em), [Ca²⁺]., and channel phosphorylation.^[84] It has been demonstrated that BK_Ca does not modulate HPV in hypoxic condition, but is responsible for hypoxia-induced relaxation due to the resulting increased Ca²⁺ sensitivity, suggesting that BK_Ca might play a major role in the regulation of vascular tone in response to hypoxia.^[85] Taken all together, chronic PASMCs exposure to hypoxia modifies the ionic movements across the PASMCs, which leads to an increased intracellular K⁺ and Ca²⁺ concentration and disrupts tightly regulated mechanisms such as vascular tone and balance between cellular proliferation and apoptosis.

SIGNAL TRANSDUCTION: CRITICAL PATHWAYS THAT MAINTAIN AND AMPLIFY DISEASE PROGRESSION

Disrupted TGF-β signaling

The heritable (HPAH) and idiopathic (iPAH) forms of PAH have been linked with loss-of-function mutations in the bone morphogenetic protein receptor 2 (BMPR2) gene, located on the long arm of the chromosome 2q31–33, and the transforming growth factor β (TGF-β) superfamily of receptors pathways.^[86] The bone morphogenetic proteins (BMPs) ligands are essential to cellular proliferation and apoptosis and play a key role in embryogenesis.^[87] When the BMP2 ligand binds to BMPR2, it can signal through different pathways, including pSmad1/5,^[88] p-p38,^[89] pERK, JNK, and Akt/PI3K.^[90,91] Mutations in BMPR2 have been reported in 70% or more of HPAH and in approximately 10–20% of patients with sporadic iPAH.^[92] However, the penetrance of HPAH remains low with 80% of family members carrying BMPR2 mutations that will never develop PAH.^[93] A BMPR2 mutation is rarely seen in patients with PAH related to a congenital left-to-right shunt^[94] and is also rarely seen in patients with PAH-associated with appetite suppressants.^[95] The functional link between mutations in BMPR2 and PAH is reinforced by the fact that, independent of a mutation in BMPR2, most iPAH patients have reduced BMPR2 protein expression.^[96]

Increased ET-1 production has been linked to abnormal BMPR2 signaling; however, it remains to be clearly demonstrated since the interplay and balancing effects between BMPR2 and TGF-β is complex. A recent study presents new elements about this concept by showing that BMPR2 knockdown increases Smad1 and Smad5 phosphorylation and ET-1 production in human lung microvascular ECs.^[97] The global gene expression in iPAH is distinct from HPAH and healthy individuals. The authors have related that when not triggered by BMPR2 mutation, iPAH could at least in part possibly originate from increased expression of the transcription factor MSX1—a regulator of BMPs expression—that shows a four-fold higher level in iPAH patients than in healthy controls. Interestingly, MSX1 have been also linked with capillary regression.^[98]

Additional genes have been identified as associated with mutations in the effectors of the signaling pathway and the TGF-β superfamily of receptors: Activin receptor-like kinase 1 (ALK1), endoglin (ENG),^[99] and more recently identified, Caveolin-1 (CAV1).^[100] Mutations in ALK1^[101] and ENG^[102] have been observed in patients with hereditary hemorrhagic telangiectasia (HHT), an autosomal dominant vascular dysplasia with abnormally dilated vessels forming mucosal and visceral telangiectasia in association with PAH.^[101,103] Animal models deepen the implication of ALK1 in the development of PAH as ALK1-deficient mice develop spontaneous pulmonary hypertension. In contrast, BMPR2-heterozygous mice require additional perturbations such as hypoxia and serotonin, or inflammation, to elicit an exaggerated pulmonary hypertensive phenotype^[104] indicating a potentially more pathologic effect of ALK1 mutation compared to BMPR2 mutation. Mutations in CAV1 have been assodateci with PAH in a large family with HPAH where six individuals were affected over three generations.^[100] Those mutations lead to a decreased formation of caveolae, a subtype of specialized microdomains known as lipid rafts that are rich in cell surface receptors, critical to initiation of a cellular signaling cascade, such as NO pathway and G-protein coupled receptor, and, therefore, important to the homeostasis of the pulmonary vasculature.^[100,105]

The STAT3/NFAT pathway

Signal transducer and activator of transcription 3 (STAT3) implication in aberrant PASMC proliferation has been recently highlighted.^[106] STAT3 is a transcription factor activated by phosphorylation^[107] in response to cytokines (IL-6, TNF),^[108] growth factors (PDGF, VEGF),^[108] and vasoconstrictor agents (ET-1 and angiotensin 2 [Ang2]).^[109] Thus, different types of receptors can be involved in STAT3 signaling such as RTK, G-protein coupled receptors (GPCR), or TNF type receptors. Several downstream STAT3 targets have been identified and the role of STAT3 as a signaling hub has been reinforced. STAT3 not only integrates several upstream signals but also redistributes this signal downstream to enhance several cellular processes to sustain the proproliferative and antiapoptotic phenotype by amplifying the signal. STAT3 has been associated with increased expression of Piml.^[110] Enhanced expression of Pim1 promotes the activation of NEAT, which, therefore, promotes inflammation by enhancing cytokine secretion,^[111] proliferation of smooth muscle cells by decreasing K⁺ channels activity which promotes increased [Ca²⁺].,^[112] and apoptosis resistance by increasing the mitochondrial membrane potential. STAT3 also triggers Survivin expression^{[106,113,114]} through activation of the transcription factor Krüppel-like factor 5 (KLF5).^[115] Once activated, this zinc-finger-type transcription factor promotes the upregulation of the cyclin B1 and triggers the expression of Survivin, and then contributes to PASMC proliferation and survival. STAT3 is also activated by mechanical stress associated with pressure overload, including shear stress and cyclic strain, through the stimulation of integrin type receptors.^[116] Interestingly, STAT3 axis has also been implicated in the downregulation of the endothelial nitric oxide synthase (eNOS] expression and subsequent decrease in NO generation.^[117] Indeed, the protein kinase delta (PKCδ) activation following ET-1 stimulation in ovine fetal PAECs has been associated with STAT3 phosphorylation and increased binding of STAT3 on the eNOS promoter, resulting in inhibition of eNOS expression.^[117] Thus, STAT3 pathway might be at least in part responsible for the downregulation of the NO signaling in PAH.

Peroxisome proliferator-activated receptor γ

Peroxisome proliferator-activated receptor γ (PPARγ) is a transcription factor well known to be implicated in PAH etiology. It has been suggested that PPARγ is a downstream target of the BMPR signaling pathway.^[118] According to the recent literature, PPARγ is involved in a wide range of physiological processes from lipogenesis to inflammation and also plays a critical role in the pathogenesis of PAH because of its effect on proliferation and migration. Hansmann and colleagues demonstrated that the antiproliferative effect of BMP2 was BMPR2/PPARγ/ApoE dependent^[119] and that ApoE knockout mice on a high-fat diet develop PAH, which can be reversed by the administration of PPARγ agonist.^[120] PPARγ agonist has quickly been considered a possible therapeutic intervention. The activation of PPARγ with insulin-sensitizing agents thiazolidinedione (TZD) in this model help reduce systemic blood pressure, attenuate the formation of arteriosclerotic lesions, and block the arterial wall remodeling process. The use of rosiglitazone allows for the attenuation of pathological arterial remodeling and neomuscularization of arteries in the lung and, therefore, without being able to prevent the development of pulmonary hypertension in rats exposed to chronic hypoxia.^[121,122] This drug might have therapeutic application with PAH patients. Questions have been raised about its cardiovascular side effects, but clinical results are still conflicting about its real ratio between risks and efficacy.^[123] We recently demonstrated that the receptor of advanced glycation end-products (RAGE) was an upstream target of PPARγ in PAH.^[124] Indeed, this protein is implicated in a wide range of pathologies such as cancer, Alzheimer's disease, and vascular diseases.^[125–127] From a molecular point of view, RAGE seems to be implicated in many cellular signaling pathways like inflammation, proliferation, and migration,^[128,129] all of which are implicated in PAH pathogenesis. Also, RAGE is highly upregulated in PAH lung tissues.^[124,130] Thus, we showed that RAGE accounts for STAT3 activation as well as BMPR2 and PPARγ downregulation in PAH-PASMCs, the same phenotype observed when control PASMCs are exposed to S100A4, a RAGE ligand, known to be increased in PAH.^[131] Moreover, RAGE inhibition in PAH-PASMCs and in PAH animal models (MCT and Sugen) reverses established PAH, illustrated by decreasing mPAP, vascular remodeling, and RV hypertrophy.

Furthermore, in human pulmonary arterial endothelial cells (PAEC) from PAH patients, a BMPR2-mediated transcriptional complex between PPARγ and β-catenin have been characterized and a disruption of this complex impair BMP-mediated PAEC survival.^[119,132] The human PAEC also presents a reduced expression of apelin when compared to PAEC from healthy controls. Apelin have been established to suppress proliferation and to induce apoptosis in PASMC, like BMP-2/BMPR2 ligand complex.^[132,133] Cell culture experiments made by Alastalo and colleagues have shown that apelin-deficient PAEC were prone to apoptosis, and were promoting excessive PASMC proliferation.^[132] Administration of apelin was able to reverse PAH in mice model where the production of apelin was reduced from the deletion of PPARγ in ECs. Therefore, apelin might represent a therapeutic alternative to treat PAH.

Notch signaling in PAH

Notch signaling is an essential mechanism involved in the cell-fate determination during embryonic development. The Notch receptors and ligands are bound to the cellular membrane. The signal transduction occurs by cell-to-cell contact, leading to a proteolytic cleavage of the Notch receptor, including a final cleavage by the γ-secretase to release the receptor's intracellular domain. The intracellular domain of the Notch receptor translocates to the nucleus to form an active transcription activator complex with the DNA binding protein CBF-1 and activates transcription of HES and HEY genes as its downstream targets.^[134] Notch is implicated in many aspects of vascular development like vasculogenesis, angiogenesis, and differentiation of vascular smooth muscle cells.^[135] Notch 3 targets gene HES-5, which is expressed exclusively in smooth muscle cells in adults and might be involved in SMCs identity, maturation, and proliferation.^[136,138] In vitro PASMCs from PAH patients display higher mRNA and protein levels of Notch 3 and HES-5 than in PASMCs from healthy patients. Overexpression of Notch intracellular domain leads to an increased growth rate of PASMCs, whereas Notch 3-knockout mice lack this proliferative effect.^[139] Also, treatment with γ-secretase inhibitor, thus blocking Notch receptor cleavage, attenuates hypoxiainduced PAH in mice. Therefore, these data indicate that high levels of Notch 3 is associated with the development of PAH, favoring a vascular proliferative phenotype.

MicroRNAs: FEED-FORWARD LOOP THAT CLOSES THE SYSTEM

Approximately a decade ago, a 22 nucleotide-non-coding RNA(s) called micro RNA(s) (miR[s]) was discovered in mammalian cells.^[140] It now offers us a new vision on post-transcriptional regulatory mechanisms^[141] and a new tool to understand physiological and pathological process. Briefly, miRs can inhibit translation by any of the four following mechanisms: (1) Inhibiting translation at a postinitiation step without reducing mRNA abundance, polyadenylation, or polyribsomal content by targeting mRNAs for sequestration in P-bodies; (2) inhibiting translation initiation via a cap-dependent or poly(A)-dependent mechanism, or by affecting physically ribosomal fixation; (3) inducing deadenylation of mRNAs; and (4) inducing direct degradation of the target by other mechanisms.^[142–146] There is increasing evidence for the implication of miRNA in many diseases such as cancer,^[147] brain disorder,^[148] and lung diseases.^[149] Interestingly, more than 1,200 miRs have been identified in mammalians cells^[150] with, for most of them, a tissue specific expression. Only few miRs have been shown aberrantly expressed in PASMCs and in ECs.

In cancer among others, downregulation of miR-204 has been observed and linked with enhanced cell proliferation and membrane cell depolarization,^[151] which are also found in PAH pathogenesis.^[83,152] Interestingly, miR-204 downregulation in PAH-PASMCs was found to correlate with PAH severity and to be associated with a higher proliferative rate and resistance to apoptosis.^[113] By digging into this concept, and using ChIP-PCR experiments, the authors determined that the downregulation of miR-204 is dependent of STAT3, which binds the promoter of miR-204 host gene TRPM3 and decreases the transcription of the package. miR-204 have been identified to target and downregulate the Src homology 2 domain-containing phosphatase 2 (SHP2), an Src activator; thus when down-regulated, miR-204 enhances a constitutive activation of Src and STAT3. This positive feedback loop involving miR-204 sustains the proproliferative and apoptotis resistant pathologic PASMC behaviour. In addition to the constitutive activation of Src, the downregulation of miR-204 seems to indirectly downregulate BMPR2 by upregulating IL-6 secretion,^[153] a potent STAT3 activator, suggesting the existence of another feed-forward loop between miR-204 and STAT3. IL-6 has been demonstrated as upregulated in PAH, although without identifying the cause of this higher secretion.^[154] On the other hand, increased IL-6 has been linked to the STAT3-dependant expression of miR-17/92.^[155] miR-17/92 has been showed to directly bind BMPR2 and enhance its degradation, suggesting that STAT3 might be responsible for the BMPR2 downregulation. As mentioned above, BMPR2 is involved in the activation of PPARγ which counteracts the STAT3 signaling; however, BMPR2 is also an interacting partner of Src (enhances Src sequestration and decreases its activity). Therefore, STAT3-dependent downregulation of BMPR2 might be associated in two other ways for STAT3 to maintain its own activation. As miRs are also used as biomarker s in oncology, miR-204 could probably endorse this role as it proved to be significantly decreased in the buffy coat of PAH patients.^[113,156]

Recent advances in basic science deepen our knowledge about miR-145 andmiR-143. These miRNAs are organized in a cluster regulated by Src and p53 pathways,^[157] and they are tightly integrated into a core transcriptional network process involved in smooth muscle differentiation and proliferation. miR-145 appears to direct the smooth muscle cell fate and miR-143 regulates the quiescent and proliferative state of smooth muscle cells.^[158] Using a Smad4-mediated transcription, the TGF-β stimulates the expression of the serum response factor and its coactivators, myocardin (Myocd), whereas BMP4 stimulates the myocd-related transcription factor A (MRTF-A) through nuclear translocation. The subsequent upregulation of myocd and MRTF-A induce miR-143 and miR-145 transcription, which repress Krüppel-like factor 4 (KLF4) expression. Therefore, it allows enhanced binding of myocd and MRTF-A to a regulatory DNA element called the CArG box, which promotes contractile gene expression of smooth muscle cells. An unrepressed KLF4 expression reduces excessive binding of myocd and MRTF-A to CArG boxes, which promotes low contractile gene expression of smooth muscle cells.^[159] The plexiform lesion and concentric lesions are typically found in severe PAH, and present an abnormal expression of miR-143/miR-145. Plexiform and concentric lesions have increased BMP4 gene expression. Moreover, plexiform lesions have increased TGF-β expression when compared to concentric lesions. The expression of miR-145 was increased in mice exposed to hypoxia and in PAH patients with BMPR2 mutation.^[160] miR-143 and miR-145 were significantly higher in concentric lesions compared to plexiform lesions.^[161] This points out a possible independent role of miR-145 and miR-143 in characteristic PAH lesions. Their reduced expression in plexiform lesions compared to concentric lesions concurs with the more proliferative profile of this type of lesion. Figure 2 illustrates the integration of miR-204 and miR-143/miR-145 in the pathobiology of PAH.

Figure 2:

Schematic diagram illustrating the different pathways where miRs are playing an important role in the cellular proliferation and apoptosis of the PASMCs. The increased expression of STAT3 leads to an increased expression STAT3/Pim-1/Src/NFAT axis, which leads to cellular proliferation and reduced apoptosis. TGF-β increases expression of Myocd through Smad4 and BMP4 increases expression of MRTF-A through nuclear translocation, which allow an increased expression of miR-143/miR-145 who then inhibits KLF4. The repressed expression of KLF4 allows an enhanced binding of Myocd and MRTF-A to the CArG box of contractile gene who then promotes PASMCs contraction. If KLF4 is not repressed, there is no enhanced binding of Myocd and MRTF-A to the CArG box of contractile gene, who then presents a low contractile expression. PASMCs = pulmonary arterial smooth muscle cells; VEGF = vascular endothelial growth factor; PDGF = platelet-derived growth factor; AGE = advanced glycation end-product; RAGE = receptor of advanced glycation end-product; Src = sarcoma viral oncogen homolog; STAT3 = transcription factor signal transducer and activator transcription 3; miR = micro-ARN; Pim-1 = proto-oncogene Provirus integration site for Moloney murine leukemia virus; NFAT = nuclear factor of activated T cells; TGF-β = transforming growth factor β; BMP4 = bone morphogenetic protein 4; BMPR2 = bone morphogenetic protein receptor 2; Myocd = myocardin; MRTF-A = Myocd-related transcription factors A; KLF4 = Krüppel-like factor 4.

miR-126 is mainly expressed in ECs and plays a key role in a wide range of physiological and pathologic processes such as cancer,^[162,163] brain disorder, regulation of angiogenic signaling, vascular integrity,^[164] and recently in PAH, where its expression is deregulated specifically in plexiform lesion.^[161] miR-126 is important for vascular integrity, EC proliferation, and neovascularisation.^[165] In ECs, its expression is negatively regulated by ET-1 and ET-2 and by the Src pathway. Interestingly, miR-126 has been recently shown to interact with the 3-phosphoinositide-dependent kinase (PI3K/Akt) pathway and the mitogen-activated protein kinase (MAPK) pathway. Its action seems to be indirect, regulating the expression of negative and/or positive regulators such as the Sprouty related EVH1 domain containing protein 1 (SPRED1), phosphoinositide kinase 3 regulatory subunit 2 (PIK3R2), VEGF, insulin receptor substrate 1 (IRSI), or the epidermal growth factor like domain containing protein 7 (EGFL7). Furthermore, mir-126 interacts and regulates the expression of factors involved in apoptosis, modulation of cell cycle arrest, notably by SOX2 and angiogenesis and tumor necrosis factor alpha (TNFα) signaling.^[166,167]

Recent reports have identified other miRs as actors in PAH pathobiology. Of interest, plasma miR-150 levels were shown to be reduced and to correlate with survival in PAH.^[168] The mechanism by which miR-150 is reduced, however, remains unknown; its expression impairment leads to decreased peripheral number NK cells^[169] and B1 cell expansion and to an enhanced humoral immune response.^[170] A link could be established with a variety of targets contributing to the deregulation of PASMCs, ECs,^[171] and the hypertrophic response of the RV to increased mPAP.^[172] Also, miR-150 has been linked with vascular stem cell recruitment, in particular endothelial progenitor cells (EPC), that take active part in PAH pathobiology^[173] Recent reports on hypoxia-regulated miRs have identified miR-210 as being the most upregulated by hypoxia,^[174–177] butmiR-21 also appears to be highly upregulated by hypoxia, mainly in tumor cell lines,^[178,179] suggesting that it may have an important role in cell growth and proliferation. On the other hand, it is interesting to observe that a variety of miRs can be downregulated by hypoxia.^[180,181] miR-21 appears to be key regulator of hypoxia responses, linked to abnormal proliferation andmigration of PASMCs.^[182] miR-17 impairs EC angiogenic function by targeting the cell cycle inhibitor p21 and the Janus kinase (JAK1) and is upregulated by hypoxia.^[183] Treatment with an antagomir-17 has proved its efficacy on MCT rat model by reducing PH, right heart hypertrophy, and by improving the right ventricular function.^[184] Moreover, Drakes, Bogaard, and colleagues also demonstrated the implication of miRNAs in RV hypertrophy and failure.^[185] This could also provide information on PAH patients' outcomes as RV condition is the main predictor of PAH survival. These oligonucleotides are often the cause of protein misexpression and transcription factor constitutive activation, and are thus great targets to stop inappropriate enrollment of processes that maintain an ongoing progression and worsening of the disease. Thus, miRs are actually seen as a useful diagnostic biomarker and prognostic tool^[186] as well as a potential target for future therapeutic interventions.^[113] However, more studies are needed to explore the toxicity and risks of miRs therapies on humans.

CRITICAL LACK OF SPECIFIC BIOMARKERS IN PAH

In the current clinical practice, the only used biomarker in PAH remains the N-terminal prohormone of brain natriuretic peptide (NT-pro BNP). It was originally used in the screening and diagnosis of congestive heart failure (CHF), and also to establish CHF prognostic as high NT-pro BNP blood level generally indicates impaired cardiac function and shows poor outcome.^[187] The natriuretic peptide does not suit the role of the gold standard biomarker in PAH as it does not reflect changes in the pulmonary vasculature remodeling, but more likely reflects RV stress.^[188] Therefore, we don't have biomarkers to detect early stages of the disease and to predict the ongoing vascular remodeling. Current biomarkers are also inefficient to predict the quality and sustainability of the RV adaptive response which deteriorates with the progression of the disease and determines the outcome. Elevated circulating levels of Ang2 were associated with impaired hemodynamics, elevated NT-pro BNP, and unfavorable outcome. Kümpers et al. identified that patients' survival rate was 100% atone year when they had baseline Ang2 < 2.9 ng/mL compared to 78% in patients with baseline Ang2 > 2.9 ng/mL. The patients' survival rate identified during follow-up were 92% versus 63% after two years, 88% versus 54% after three years, and 88% versus 46% after four years, respectively. Therefore, Ang2 seems to have a future as a potential biomarker of severity and outcome for PAH patients.^[23] Therapeutic potential of miRNAs should also be confirmed, but they could become important biomarkers, as they are already used as putative diagnostic biomarkers in myocardial infarction, heart failure, coronary artery disease, type 2 diabetes mellitus,^[189] and cancer.^[190] For PAH, human PAH-PASMCs and cells from the buffy coat of PAH patients have many similarities, as so, they both activate NFAT pathway. miR-204 have been shown to be reduced in PAH patients buffy coat and in extend in PAH-PASMCs, suggesting that miR-204 can become a reliable biomarker.^[113] Plasma level of miR-150 also holds promising future,^[168] although larger studies are needed. Elevated expression of Pim1 in the buffy coat from PAH patients' makes it an interesting biomarker as well.^[106,191] It seems not to be elevated in other inflammatory disease, ruling out PAH patients with scleroderma, a common cause of PAH, increasing at the same time its specificity to PAH. New elements in the clinical toolbox may help to diagnose and treat the disease earlier and thus to improve the outcome drastically.

CURRENT AND FUTURE TREATMENTS IN PAH

Improvement of current therapies in PAH

Endothelin receptor antagonists (ERAs) such as bosentan and ambrisentan were the first orally-administered drugs for PAH treatment and are still currently used in clinics. ERAs are associated to improved cardiopulmonary hemodynamic, exercise capacity and functional class.^[192,193] Tissue penetration of bosentan and ambrisentan is limited.^[194] However, a tissue-targeting endothelin receptor antagonist called macitentan was recently developed to resolve this issue.^[195] A Phase III multi-center study on 743 patients, SERAPHIN, has been initiated to assess the effects of macitentan on mortality and morbidity of macitentan on symptomatic PAH patients. The results of this study are presented in different symposia through the current year. Publication can also be expected throughout the current year.

Treatment with epoprostenol, an intravenous (IV] prostacyclin, is known to improve hemodynamic parameters^[196] and symptoms as well as to improve survival in patients with iPAH.^[197] However, continuous administration via a catheter is very inconvenient for patients.^[6] IV^[198] and inhaled tresprostinil^[199] and inhaled iloprost^[200] are also known to improve hemodynamic parameters. Finally, a Phase II study demonstrated that selexipag, an oral selective prostacyclin receptor agonist, is efficient to reduce pulmonary vascular resistance.^[201]

Presently, sildenafil and tadalafil are two PDE-5 inhibitors used for PAH treatment. They both improve exercise capacity, hemodynamic parameters, and quality of life.^[202–204] Vardenafil, also a PDE-5 inhibitor (consisting of a different chemical structure) was recently studied in a randomized, double-blind, placebo-controlled study and shows that an oral dose of 5 mg twice daily improves exercise capacity, symptoms, hemodynamics, and clinical outcome.^[205] Recently, a novel agent riociguat was developed. Riociguat is an oral soluble guanylate cyclase (sGC) stimulator that transforms guanosine 5′-trisphosphate to cGMP independently of the NO level.^[40] Studies on animal models showed that riociguat increases hemodynamic, reduces remodeling, and right heart hypertrophy.^[206] A Phase II trial on riociguat in PAH showed improvement in 6-Minute Walk Distance (6MWD) and a decrease in pulmonary vascular resistance.^[207] Phase III trials are presently underway and the results are expected soon.

Future therapies in PAH

As previously mentioned, the current treatments are inefficient to improve survival of PAH patients and to reverse the disease. The need of new therapeutic strategies that can cure PAH by acting on remodeling and proliferation is urgent. Similarities found between cancers and PAH, like hyperproliferation, resistance to apoptosis, and cellular metabolism disorders^[208] have generated interest for antitumor therapies that may also be applied to the treatment of PAH.

Targeting growth factor. Tyrosine kinase inhibitors, for example, are currently being used against cancer and are now under several clinical trials for PAH. One of them, imatinib, a PDGFR inhibitor, was originally developed for the treatment of different tumors^[209] and was tested in several PAH experimental models. It was shown thatimatinib can reverse advanced PAH, decrease right ventricular hypertrophy, and improve cardiac output.^[32] In vivo, imatinib has a positive effect on PASMCs by decreasing apoptosis resistance and proliferation.^[210] Case studies showed that imatinib can improve the hemodynamic parameters and exercise capacity of severe PAH patient.^[35] A Phase II clinical trial was performed on 59 functional Class II-IV PAH patients. The aim of this study was to assess efficacy, tolerability and safely of imatinib in pulmonary arterial hypertension. Patients under imatinib improved significantly their hemodynamic parameters with a decreased PVR and an increase in the cardiac output.^[34] However, those results did not reach the primary end-point in 6-MWD with a difference after 24 weeks of +22 m for the imatinib group and −1 m for the placebo group. Moreover, severe side effects including cardiac arrest, syncope, liver dysfunction, and PAH worsening occurred in 39% of the patients under imatinib. The Phase III trials, IMPRES, were initiated to evaluate the efficacy and safely of imatinib in severe PAH in 202 patients. The primary end-point was achieved with a significant change of 32 m in the mean placebo-corrected treatment effect on the 6MWD. Patients under imatinib improved significantly their hemodynamic parameters with significant change in mPAR CO, PVR, and right atrial pressure. However, functional class, time to clinical worsening, and mortality did not differ between treatments.^[211] Targeting arterial remodeling by the inhibition of PDGF with imatinib is still considered a potential PAH medication mostly for severe patients, although other studies on liver toxicity and cardiotoxicity need to be conducted.^[212] Nilotinib is an active tyrosine kinase inhibitor that was also developed for treatment of chronic myelogenous leukemia.^[192] Studies on animals suggest that nilotinib is more effective than imatinib since it reduced right heartpressure and hypertrophy. A Phase II study is underway to assess efficacy, tolerability, and safely of nilotinib on 66 functional Classes II-IV PAH patients. The primary end-point in this case is a change in PVR. Even if nilotinib tends to be safer than imatinib, this potential therapy still represents a risk of cardiac complications and sudden death.^[6] Sorafenib is a multikinase inhibitor used for the treatment of renal cell carcinoma and hepatocellular carcinoma. Sorafenib inhibits tyrosine kinases PDGF and VEGF receptor and also serine/threonine kinases including RAF-1, which are related to myocardium hypertrophy. A study on monocrotaline rats showed that sorafenib can reverse experimental pulmonary hypertension and decrease myocardial hypertrophy.^[195] A preliminary study on 12 PAH patients was initiated to assess the safely of sorafenib in PAH. This study showed that 200 mg twice daily of sorafenib is well-tolerated by PAH patients and results in an increase in exercise capacity. Moderate skin reactions, diarrhea, and alopecia were the most common adverse events caused by the treatment.^[213] However, studies on more patients need to be assessed.

Targeting STAT3. Dehydroepiandrosterone (DHEA] is a hormone known for its vasodilator properties by acting on K⁺ channels.^[214] However, studies on animal models showed that DHEA has an antiproliferative and proapoptotic effect on pulmonary arteries. In fact, Paulin and colleagues demonstrated that DHEA can inhibit the Src/STAT3 axis and by this process improve PAH and decrease RV hypertrophy in monocrotaline rats and human PASMCs.^[153] In a recent study, eight patients with pulmonary hypertension associated with chronic obstructive pulmonary disease were daily treated with 200 mg of DHEA. After three months, all patients showed an improved 6MWD and pulmonary hemodynamic without changes in their gas exchange parameters.^[215]

Plumbagin (PLB], or 5-hydroxy-2-methyl-1, 4-naphthoquinone, is an organic compound known to have anticancer properties on different tumor cells.^[216] A study on nonsmall cell lung cancer (NSCLC) culture has demonstrated that PLB has apoptotic and antiproliferative effects on NSCLC by the downregulating Survivin and growth factor receptor expression.^[217] Moreover, another study on myeloma cells showed that PLB suppresses STAT3 activation which is implicated in PAH remodeling.^[218] An in vitro study on human PASMCs presented that plumbagin can inhibit PASMC proliferation and resistance to apoptosis by blocking the activation of STAT3/NFAT. Also, it was demonstrated in vivo that oral administration of plumbagin reduced mPAP, vascular remodeling, and right ventricular hypertrophy on sugen and MCT rats.^[219]

Circulating progenitor cells. The blood vessels form a complex network of arteries, capillaries, and veins designed to transport micromolecules, macromolecules, gases, and fluids to every cell in the organism. The formation of this network goes through several stages during embryonic development and postnatal development, including vasculogenesis and angiogenesis. Vascular remodeling is needed for the development of a strong network able to sustain shear stress while being able to transport oxygen and nutriments to the physiological environment. We explored earlier the mechanisms implicating VEGF and VEGFR2 expression and leading to endothelial dysfunctions. Proangiogenic factors also have a role in the abnormal vascular remodeling observed in PAH. Defective mobilization and recruitment of endothelial progenitor cells (EPCs] have been implicated in the sustainability of the PAH phenotype.^[220] Patients with Eisenmenger syndrome and IPAH have a reduced number of EPCs.^[221,222] However, investigators have also found an increased number of EPCs in patients with other forms of PAH.^[223,224] Thus, despite the presence of EPCs, there is no successful repair of the damaged pulmonary endothelium. Additionally, an increased expression of progenitor cell markers has been observed in lung tissue from patients with IPAH compared with control lung tissue.^[222] Angiopoietin are angiogenic factors essential to vascular development and maturation. Ang1 and its antagonist Ang2 are needed to bind the extracellular domain of the tyrosine kinase receptor Tie-2, which is mainly expressed in ECs. Ang1 stabilize the development of newly formed blood vessels by recruiting mural cells and promoting the maturation and structure integrity of the vessels. In contrast, the presence of Ang2 destabilizes the vessels in the presence of VEGF or promotes vascular regression and ECs death in the absence of VEGF. In patients with iPAH, all angiogenic factors were elevated while histological studies showed that Ang2 mRNA expression was over-expressed in plexiform lesions from IPAH patients' lung tissue.^[23]

CONCLUSION AND FUTURE DIRECTION

In the past five years, the understanding of molecular origins of pulmonary arterial hypertension has given rise to numerous research and important discoveries. In fact, the increased knowledge in pathogenesis and the presentation of promising therapy in PAH such as miRNAs, tumor suppressors, and oncoprotein inhibitors provide significant hope to cure this fatal disease. As studies targeting vascular remodeling using antiproliferative agents obtained great success in experimental models, and since many other studies are presently underway, it is allowable to believe that the next decades will be determinant to cure PAH.

Footnotes

Source of Support: Nil

Conflict of Interest: None declared.

References

Simonneau

Galiè

Rubin

Langleben

Seeger

Domenighetti

. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5–12S.

Peacock

Murphy

McMurray

Caballero

Stewart

. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104–9.

Humbert

Sitbon

Chaouat

Bertocchi

Habib

Gressin

. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med 2006;173:1023–30.

Badesch

Champion

Sanchez

Hoeper

Loyd

Manes

. Diagnosis and assessment of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S55–66.

Humbert

Sitbon

Chaouat

Bertocchi

Habib

Gressin

. Pulmonary arterial hypertension in France: Results from a national registry. Am J Respir Crit Care Med 2006;173:1023–30.

McLaughlin

. Looking to the future: A new decade of pulmonary arterial hypertension therapy. Eur Respir Rev 2011;20:262–9.

Kim

Ahn

Strother

Morris

Masliah

. Distribution of obstructive intimal lesions and their cellular phenotypes in chronic pulmonary hypertension. A morphometric and immunohistochemical study. Am J Respir Crit Care Med 2000;162(4 Pt 1):1577–86.

Firth

Mandel

Yuan

. Idiopathic pulmonary arterial hypertension. Dis Model Mech 2010;3:268–73.

Stenmark

Meyrick

Galie

Mooi

McMurtry

. Animal models of pulmonary arterial hypertension: The hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013–32.

10.

Kuhr

Smith

Song

Levitan

Yuan

. New mechanisms of pulmonary arterial hypertension: Role of Ca²? signaling. Am J Physiol Heart Circ Physiol 2012;302:H1546–62.

11.

Ward

McMurtry

. Mechanisms of hypoxic pulmonary vasoconstriction and their roles in pulmonary hypertension: New findings for an old problem. Curr Opin Pharmacol 2009;9:287–96.

12.

Weissmann

Dietrich

Fuchs

Kalwa

Dumitrascu

. Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U S A 2006;103:19093–8.

13.

Vonk-Noordegraaf

Galiè

. The role of the right ventricle in pulmonary arterial hypertension. Eur Respir Rev 2011;20:243–53.

14.

Chin

Kim

Rubin

. The right ventricle in pulmonary hypertension. Coron Artery Dis 2005;16:13–8.

15.

Handoko

de Man

Allaart

Paulus

Westerhof

Vonk-Noordegraaf

. Perspectives on novel therapeutic strategies for right heart failure in pulmonary arterial hypertension: Lessons from the left heart. Eur Respir Rev 2010;19:72–82.

16.

Gan

Lankhaar

Marcus

Westerhof

Marques

Bronzwaer

. Impaired left ventricular filling due to right-to-left ventricular interaction in patients with pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2006;290:H1528–33.

17.

Marcus

Gan

Zwanenburg

Boonstra

Allaart

Götte

. Interventricular mechanical asynchrony in pulmonary arterial hypertension: Left-to-right delay in peak shortening is related to right ventricular overload and left ventricular underfilling. J Am Coll Cardiol 2008;51:750–7.

18.

Vonk-Noordegraaf

Marcus

Gan

Boonstra

Postmus

. Interventricular mechanical asynchrony due to right ventricular pressure overload in pulmonary hypertension plays an important role in impaired left ventricular filling. Chest 2005;128(6 Suppl):628–30S.

19.

Mauritz

Marcus

Westerhof

Postmus

Vonk-Noordegraaf

. Prolonged right ventricular post-systolic isovolumic period in pulmonary arterial hypertension is not a reflection of diastolic dysfunction. Heart 2011;97:473–8.

20.

Schermuly

Ghofrani

Wilkins

Grimminger

. Mechanisms of disease: Pulmonary arterial hypertension. Nat Rev Cardiol 2011;8:443–55.

21.

Sakao

Tatsumi

. The effects of antiangiogenic compound SU5416 in a rat model of pulmonary arterial hypertension. Respiration 2011;81:253–61.

22.

Ferrara

Gerber

LeCouter

. The biology of VEGF and its receptors. Nat Med 2003;9:669–76.

23.

Kümpers

Nickel

Lukasz

Golpon

Westerkamp

Olsson

. Circulating angiopoietins in idiopathic pulmonary arterial hypertension. Eur Heart J 2010;31:2291–300.

24.

Geiger

Berger

Hess

Bogers

Sharma

Mooi

. Enhanced expression of vascular endothelial growth factor in pulmonary plexogenic arteriopathy due to congenital heart disease. J Pathol 2000;191:202–7.

25.

Tuder

Chacon

Alger

Wang

Taraseviciene-Stewart

Kasahara

. Expression of angiogenesis-related molecules in plexiform lesions in severe pulmonary hypertension: Evidence for a process of disordered angiogenesis. J Pathol 2001;195:367–74.

26.

Jonigk

Golpon

Bockmeyer

Maegel

Hoeper

Gottlieb

. Plexiform lesions in pulmonary arterial hypertension composition, architecture, and microenvironment. Am J Pathol 2011;179:167–79.

27.

Tuder

Groves

Badesch

Voelkel

. Exuberant endothelial cell growth and elements of inflammation are present in plexiform lesions of pulmonary hypertension. Am J Pathol 1994;144:275–85.

28.

Voelkel

Vandivier

Tuder

. Vascular endothelial growth factor in the lung. Am J Physiol Lung Cell Mol Physiol 2006;290:L209–21.

29.

Campbell

Zhao

Sandhu

Stewart

. Cell-based gene transfer of vascular endothelial growth factor attenuates monocrotaline-induced pulmonary hypertension. Circulation 2001;104:2242–8.

30.

Mizuno

Farkas

Al Husseini

Farkas

Gomez-Arroyo

Kraskauskas

. Severe pulmonary arterial hypertension induced by SU5416 and ovalbumin immunization. Am J Respir Cell Mol Biol 2012;47:679–87.

31.

Perros

Montani

Dorfmüller

Durand-Gasselin

Tcherakian

Le Pavec

. Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:81–8.

32.

Schermuly

Dony

Ghofrani

Pullamsetti

Savai

Roth

. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115:2811–21.

33.

Humbert

Monti

Fartoukh

Magnan

Brenot

Rain

. Platelet-derived growth factor expression in primary pulmonary hypertension: Comparison of HIV seropositive and HIV seronegative patients. Eur Respir J 1998;11:554–9.

34.

Ghofrani

Morrell

Hoeper

Olschewski

Peacock

Barst

. Imatinib in pulmonary arterial hypertension patients with inadequate response to established therapy. Am J Respir Crit Care Med 2010;182:1171–7.

35.

Ghofrani

Seeger

Grimminger

. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005;353:1412–3.

36.

Ogawa

Firth

Smith

Maliakal

Yuan

. PDGF enhances store-operated Ca2+ entry by upregulating STIM1/Orai1 via activation of Akt/mTOR in human pulmonary arterial smooth muscle cells. Am J Physiol Cell Physiol 2012;302:C405–11.

37.

Ciuclan

Hussey

Burton

Good

Duggan

Beach

. Imatinib attenuates hypoxia-induced PAH pathology via reduction in 5-HT through inhibition of TPH1 expression. Am J Respir Crit Care Med 2013;187:78–89.

38.

Zhang

Berezov

Wang

Zhang

Drebin

Murali

. ErbB receptors: From oncogenes to targeted cancer therapies. J Clin Invest 2007;117:2051–8.

39.

Merklinger

Jones

Martinez

Rabinovitch

. Epidermal growth factor receptor blockade mediates smooth muscle cell apoptosis and improves survival in rats with pulmonary hypertension. Circulation 2005;112:423–31.

40.

Schermuly

Janssen

Weissmann

Stasch

Grimminger

Ghofrani

. Riociguat for the treatment of pulmonary hypertension. Expert Opin Investig Drugs 2011;20:567–76.

41.

Dahal

Cornitescu

Tretyn

Pullamsetti

Kosanovic

Dumitrascu

. Role of epidermal growth factor inhibition in experimental pulmonary hypertension. Am J Respir Crit Care Med 2010;181:158–67.

42.

Hassoun

Mouthon

Barberà

Eddahibi

Flores

Grimminger

. Inflammation, growth factors, and pulmonary vascular remodeling. J Am Coll Cardiol 2009;54(1 Suppl):S10–9.

43.

Dorfmüller

Perros

Balabanian

Humbert

. Inflammation in pulmonary arterial hypertension. Eur Respir J 2003;22:358–63.

44.

Stacher

Graham

Hunt

Gandjeva

Groshong

McLaughlin

. Modern age pathology of pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;186:261–72.

45.

Ohta-Ogo

Hao

Ishibashi-Ueda

Hirota

Nakamura

Ohe

. CD44 expression in plexiform lesions of idiopathic pulmonary arterial hypertension. Pathol Int 2012;62:219–25.

46.

Ormiston

Chang

Long

Soon

Jones

Machado

. Impaired natural killer cell phenotype and function in idiopathic and heritable pulmonary arterial hypertension. Circulation 2012;126:1099–109.

47.

Kreymborg

Uchida

Gellert

Schneider

Boettger

Voswinckel

. Identification of right heart-enriched genes in a murine model of chronic outflow tract obstruction. J Mol Cell Cardiol 2010;49:598–605.

48.

Christman

McPherson

Newman

King

Bernard

Groves

. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327:70–5.

49.

Farber

Loscalzo

. Pulmonary arterial hypertension. N Engl J Med 2004;351:1655–65.

50.

Fagan

McMurtry

Rodman

. Role of endothelin-1 in lung disease. Respir Res 2001;2:90–101.

51.

Rubens

Ewert

Halank

Wensel

Orzechowski

Schultheiss

. Big endothelin-1 and endothelin-1 plasma levels are correlated with the severity of primary pulmonary hypertension. Chest 2001;120:1562–9.

52.

Moncada

Gryglewski

Bunting

Vane

. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976;263:663–5.

53.

Tuder

Cool

Geraci

Wang

Abman

Wright

. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med 1999;159:1925–32.

54.

Moncada

Palmer

Higgs

. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991;43:109–42.

55.

Pfeifer

Ruth

Dostmann

Sausbier

Klatt

Hofmann

. Structure and function of cGMP-dependent protein kinases. Rev Physiol Biochem Pharmacol 1999;135:105–49.

56.

Lucas

Pitari

Kazerounian

Ruiz-Stewart

Park

Schulz

. Guanylyl cyclases and signaling by cyclic GMP. Pharmacol Rev 2000;52:375–414.

57.

Adnot

Raffestin

Eddahibi

Braquet

Chabrier

. Loss of endothelium-dependent relaxant activity in the pulmonary circulation of rats exposed to chronic hypoxia. J Clin Invest 1991;87:155–62.

58.

Dinh-Xuan

Pepke-Zaba

Butt

Cremona

Higenbottam

. Impairment of pulmonary-artery endothelium-dependent relaxation in chronic obstructive lung disease is not due to dysfunction of endothelial cell membrane receptors nor to L-arginine deficiency. Br J Pharmacol 1993;109:587–91.

59.

Dinh-Xuan

Higenbottam

Clelland

Pepke-Zaba

Cremona

Butt

. Impairment of endothelium-dependent pulmonaryartery relaxation in chronic obstructive lung disease. N Engl J Med 1991;324:1539–47.

60.

Dinh-Xuan

Higenbottam

Wallwork

. Relationship between chronic hypoxia and in vitro pulmonary relaxation mediated by endotheliumderived relaxing factors in human chronic obstructive lung disease. Angiology 1992;43:350–6.

61.

Xuan

Dinh AT

Higenbottam

Pepke-Zaba

Clelland

Wallwork

. Reduced endothelium-dependent relaxation of cystic fibrosis pulmonary arteries. Eur J Pharmacol 1989;163:401–3.

62.

Xuan

Dinh AT

Higenbottam

Clelland

Pepke-Zaba

Cremona

Wallwork

. Impairment of pulmonary endothelium-dependent relaxation in patients with Eisenmenger's syndrome. Br J Pharmacol 1990;99:9–10.

63.

Ghofrani

Osterloh

Grimminger

. Sildenafil: From angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov 2006;5:689–702.

64.

Launay

Hervé

Peoc'h

Tournois

Callebert

Nebigil

. Function of the serotonin 5-hydroxytryptamine 2B receptor in pulmonary hypertension. Nat Med 2002;8:1129–35.

65.

Eddahibi

Guignabert

Barlier-Mur

Dewachter

Fadel

Dartevelle

. Cross talk between endothelial and smooth muscle cells in pulmonary hypertension: Critical role for serotonin-induced smooth muscle hyperplasia. Circulation 2006;113:1857–64.

66.

de Perrot

Granton

McRae

Pierre

Singer

Waddell

. Outcome of patients with pulmonary arterial hypertension referred for lung transplantation: A 14-year single-center experience. J Thorac Cardiovasc Surg 2012;143:910–8.

67.

Hervé

Launay

Scrobohaci

Brenot

Simonneau

Petitpretz

. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99:249–54.

68.

Smirnov

Robertson

Ward

Aaronson

. Chronic hypoxia is associated with reduced delayed rectifier K+ current in rat pulmonary artery muscle cells. Am J Physiol 1994;266(1 Pt 2):H365–70.

69.

Archer

London

Hampl

Nsair

Puttagunta

. Impairment of hypoxic pulmonary vasoconstriction in mice lacking the voltage-gated potassium channel Kv1.5. FASEB J 2001;15:1801–3.

70.

Gardener

Johnson

Burnham

Edwards

Heagerty

Weston

. Functional evidence of a role for two-pore domain potassium channels in rat mesenteric and pulmonary arteries. Br J Pharmacol 2004;142:192–202.

71.

Gurney

Osipenko

MacMillan

McFarlane

Tate

Kempsill

. Two-pore domain K channel, TASK-1, in pulmonary artery smooth muscle cells. Circ Res 2003;93:957–64.

72.

Olschewski

Tang

Hanze

Eul

Bohle

. Impact of TASK-1 in human pulmonary artery smooth muscle cells. Circ Res 2006;8:1072–80.

73.

Tang

Nagaraj

Morty

Gabor

Stacher

. Endothelin-1 inhibits background two-pore domain channel TASK-1 in primary human pulmonary artery smooth muscle cells. Am J Respir Cell Mol Biol 2009;41:476–83.

74.

Seyler

Duthil-Straub

Zitron

Gierten

Scholz

Fink

. TASK1 (K(2P)3.1) K(+) channel inhibition by endothelin-1 is mediated through Rho kinase-dependent phosphorylation. Br J Pharmacol 2012;165:1467–75.

75.

Wang

Juhaszova

Rubin

Yuan

. Hypoxia inhibits gene expression of voltage-gated K+ channel alpha subunits in pulmonary artery smooth muscle cells. J Clin Invest 1997;100:2347–53.

76.

Platoshyn

Golovina

McDaniel

Krick

. Chronic hypoxia decreases K(v) channel expression and function in pulmonary artery myocytes. Am J Physiol Lung Cell Mol Physiol 2001;280:L801–12.

77.

Sweeney

Yuan

. Hypoxic pulmonary vasoconstriction: Role of voltagegated potassium channels. Respir Res 2000;1:40–8.

78.

de Frutos

Diaz

Nitta

Sherpa

Bosc

. Endothelin-1 contributes to increased NFATc3 activation by chronic hypoxia in pulmonary arteries. Am J Physiol Cell Physiol 2011;301:C441–50.

79.

Fouty

McMurtry

Rodman

. Enhanced ET(A)-receptormediated inhibition of K(v) channels in hypoxic hypertensive rat pulmonary artery myocytes. Am J Physiol 1999;277(1 Pt 2):H363–70.

80.

Weigand

Sylvester

Shimoda

. Mechanisms of endothelin-1-induced contraction in pulmonary arteries from chronically hypoxic rats. Am J Physiol Lung Cell Mol Physiol 2006;290:L284–90.

81.

Lin

Leung

Zhang

Yang

Yip

Tse

. Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: A novel mechanism of hypoxic pulmonary hypertension. Circ Res 2004;95:496–505.

82.

Wang

Shimoda

Sylvester

. Capacitative calcium entry and TRPC channel proteins are expressed in rat distal pulmonary arterial smooth muscle. Am J Physiol Lung Cell Mol Physiol 2004;286:L848–58.

83.

Bonnet

Rochefort

Sutendra

Archer

Haromy

Webster

. The nuclear factor of activated T cells in pulmonary arterial hypertension can be therapeutically targeted. Proc Natl Acad Sci U S A 2007;104:11418–23.

84.

Brayden

Nelson

. Regulation of arterial tone by activation of calciumdependent potassium channels. Science 1992;256:532–5.

85.

Bonnet

Savineau

Barillot

Dubuis

Vandier

Bonnet

. Role of Ca2+- sensitive K+ channels in the remission phase of pulmonary hypertension in chronic obstructive pulmonary diseases. Cardiovasc Res 2003;60:326–36.

86.

Morrell

. Role of bone morphogenetic protein receptors in the development of pulmonary arterial hypertension. Adv Exp Med Biol 2010;661:251–64.

87.

Davies

Holmes

Deighton

Long

Yang

Barker

. BMP type II receptor deficiency confers resistance to growth inhibition by TGF-? in pulmonary artery smooth muscle cells: Role of proinflammatory cytokines. Am J Physiol Lung Cell Mol Physiol 2012;302:L604–15.

88.

Rudarakanchana

Flanagan

Chen

Upton

Machado

Patel

. Functional analysis of bone morphogenetic protein type II receptor mutations underlying primary pulmonary hypertension. Hum Mol Genet 2002;11:1517–25.

89.

Nohe

Hassel

Ehrlich

Neubauer

Sebald

Henis

. The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J Biol Chem 2002;277:5330–8.

90.

Grijelmo

Rodrigue

Svrcek

Bruyneel

Hendrix

de Wever

. Proinvasive activity of BMP-7 through SMAD4/src-independent and ERK/Rac/JNK-dependent signaling pathways in colon cancer cells. Cell Signal 2007;19:1722–32.

91.

Tian

Hood

. Bridging the BMP and Wnt pathways by PI3 kinase/Akt and 14-3-3zeta. Cell Cycle 2005;4:215–6.

92.

Rabinovitch

. Molecular pathogenesis of pulmonary arterial hypertension. J Clin Invest 2012;122:4306–13.

93.

Hamid

Cogan

Hedges

Austin

Phillips

Newman

. Penetrance of pulmonary arterial hypertension is modulated by the expression of normal BMPR2 allele. Hum Mutat 2009;30:649–54.

94.

Roberts

McElroy

Wong

Yen

Widlitz

Barst

. BMPR2 mutations in pulmonary arterial hypertension with congenital heart disease. Eur Respir J 2004;24:371–4.

95.

Humbert

Deng

Simonneau

Barst

Sitbon

Wolf

. BMPR2 germline mutations in pulmonary hypertension associated with fenfluramine derivatives. Eur Respir J 2002;20:518–23.

96.

Atkinson

Stewart

Upton

Machado

Thomson

Trembath

. Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor. Circulation 2002;105:1672–8.

97.

Star

Giovinazzo

Langleben

. ALK2 and BMPR2 knockdown and endothelin-1 production by pulmonary microvascular endothelial cells. Microvasc Res 2013;85:46–53.

98.

Kiyono

Shibuya

. Bone morphogenetic protein 4 mediates apoptosis of capillary endothelial cells during rat pupillary membrane regression. Mol Cell Biol 2003;23:4627–36.

99.

Machado

Eickelberg

Elliott

Geraci

Hanaoka

Loyd

. Genetics and genomics of pulmonary arterial hypertension. J Am Coll Cardiol 2009;54(1 Suppl):S32–42.

100.

Austin

LeDuc

Rosenzweig

Borczuk

Phillips

. Whole exome sequencing to identify a novel gene (caveolin-1) associated with human pulmonary arterial hypertension. Circ Cardiovasc Genet 2012;5:336–43.

101.

Harrison

Flanagan

Sankelo

Abdalla

Rowell

Machado

. Molecular and functional analysis identifies ALK-1 as the predominant cause of pulmonary hypertension related to hereditary haemorrhagic telangiectasia. J Med Genet 2003;40:865–71.

102.

Chaouat

Coulet

Favre

Simonneau

Weitzenblum

Soubrier

. Endoglin germline mutation in a patient with hereditary haemorrhagic telangiectasia and dexfenfluramine associated pulmonary arterial hypertension. Thorax 2004;59:446–8.

103.

Trembath

Thomson

Machado

Morgan

Atkinson

Winship

. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325–34.

104.

Jerkic

Kabir

Davies

McIntyre

Husain

. Pulmonary hypertension in adult Alk1 heterozygous mice due to oxidative stress. Cardiovasc Res 2011;92:375–84.

105.

Engelman

Zhang

Galbiati

Lisanti

. Chromosomal localization, genomic organization, and developmental expression of the murine caveolin gene family (Cav-1, −2, and −3). Cav-1 and Cav-2 genes map to a known tumor suppressor locus (6-A2/7q31). FEBS Lett 1998;429:330–6.

106.

Paulin

Courboulin

Meloche

Mainguy

de la Roque

Dumas E

Saksouk

Côté

Provencher

Sussman

Bonnet

. Signal transducers and activators of transcription-3/pim1 axis plays a critical role in the pathogenesis of human pulmonary arterial hypertension. Circulation. 2011;123:1205–1215

107.

Bromberg

Horvath

Besser

Lathem

Darnell

Jr . Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol 1998;18:2553–8.

108.

Darnell

Jr . STATs and gene regulation. Science 1997;277:1630–5.

109.

Banes-Berceli

Ketsawatsomkron

Ogbi

Patel

Pollock

Marrero

. Angiotensin II and endothelin-1 augment the vascular complications of diabetes via JAK2 activation. Am J Physiol Heart Circ Physiol 2007;293:H1291–9.

110.

Zemskova

Sahakian

Bashkirova

Lilly

. The PIM1 kinase is a critical component of a survival pathway activated by docetaxel and promotes survival of docetaxel-treated prostate cancer cells. J Biol Chem 2008;283:20635–44.

111.

Rao

Luo

Hogan

. Transcription factors of the NFAT family: Regulation and function. Annu Rev Immunol 1997;15:707–47.

112.

Bonnet

Paulin

Sutendra

Dromparis

Roy

Watson

. Dehydroepiandrosterone reverses systemic vascular remodeling through the inhibition of the Akt/GSK3-{beta}/NFAT axis. Circulation 2009;120:1231–40.

113.

Courboulin

Paulin

Giguère

Saksouk

Perreault

Meloche

. Role for miR-204 in human pulmonary arterial hypertension. J Exp Med 2011;208:535–48.

114.

Grote

Luchtefeld

Schieffer

. JANUS under stress-role of JAK/STAT signaling pathway in vascular diseases. Vascul Pharmacol 2005;43:357–63.

115.

Courboulin

Tremblay

Barrier

Meloche

Jacob

Chapolard

. Kruppel-like Factor 5 contributes to pulmonary artery smooth muscle proliferation and resistance to apoptosis in human pulmonary arterial hypertension. Respir Res 2011;12:128.

116.

Kakisis

Pradhan

Cordova

Liapis

Sumpio

. The role of STAT-3 in the mediation of smooth muscle cell response to cyclic strain. Int J Biochem Cell Biol 2005;37:1396–406.

117.

Sud

Black

. Endothelin-1 impairs nitric oxide signaling in endothelial cells through a protein kinase Cdelta-dependent activation of STAT3 and decreased endothelial nitric oxide synthase expression. DNA Cell Biol 2009;28:543–53.

118.

Galetto

Albajar

Polanco

Zakin

Rodríguez-Rey

. Identification of a peroxisome-proliferator-activated-receptor response element in the apolipoprotein E gene control region. Biochem J 2001;357(Pt 2):521–7.

119.

Hansmann

de Jesus Perez

Alastalo

Alvira

Guignabert

Bekker

. An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension. J Clin Invest 2008;118:1846–57.

120.

Hansmann

Wagner

Schellong

Perez

Urashima

Wang

. Pulmonary arterial hypertension is linked to insulin resistance and reversed by peroxisome proliferator-activated receptor-gamma activation. Circulation 2007;115:1275–84.

121.

Crossno

Garat

Reusch

Morris

Dempsey

McMurtry

. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol 2007;292:L885–97.

122.

Kim

Lee

. Rosiglitazone attenuates hypoxiainduced pulmonary arterial hypertension in rats. Respirology 2010;15:659–68.

123.

Abbas

Blandon

Rude

Elfar

Mukherjee

. PPAR-? agonist in treatment of diabetes: Cardiovascular safety considerations. Cardiovasc Hematol Agents Med Chem 2012;10:124–34.

124.

Meloche

Courchesne

Barrier

Carter

Bisserier

Roxane

. Critical role for the advanced glycation end-products receptor in pulmonary arterial hypertension etiology. J Am Heart Assoc 2013;2:e005157.

125.

Meloche

Paulin

Courboulin

Lambert

Barrier

Bonnet

. RAGE-dependent activation of the oncoprotein Pim1 plays a critical role in systemic vascular remodeling processes. Arterioscler Thromb Vasc Biol 2011;31:2114–24.

126.

Schmidt

Yan

Wautier

Stern

. Activation of receptor for advanced glycation end products: A mechanism for chronic vascular dysfunction in diabetic vasculopathy and atherosclerosis. Circ Res 1999;84:489–97.

127.

Yan

Ramasamy

Schmidt

. Mechanisms of disease: Advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008;4:285–93.

128.

Clynes

Moser

Yan

Ramasamy

Herold

Schmidt

. Receptor for AGE (RAGE): Weaving tangled webs within the inflammatory response. Curr Mol Med 2007;7:743–51.

129.

Farmer

Kennedy

. RAGE, vascular tone and vascular disease. Pharmacol Ther 2009;124:185–94.

130.

Abdul-Salam

Wharton

Cupitt

Berryman

Edwards

Wilkins

. Proteomic analysis of lung tissues from patients with pulmonary arterial hypertension. Circulation 2010;122:2058–67.

131.

Greenway

van Suylen

Du Marchie Sarvaas

Kwan

Ambartsumian

Lukanidin

. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol 2004;164:253–62.

132.

Alastalo

Vde

Perez J

Pham

Sawada

Wang

. Disruption of PPAR?/?-catenin-mediated regulation of apelin impairs BMP-induced mouse and human pulmonary arterial EC survival. J Clin Invest 2011;121:3735–46.

133.

Sorli

van den Berghe

Masri

Knibiehler

Audigier

. Therapeutic potential of interfering with apelin signalling. Drug Discov Today 2006;11:1100–6.

134.

Artavanis-Tsakonas

Rand

Lake

. Notch signaling: Cell fate control and signal integration in development. Science 1999;284:770–6.

135.

Alva

Iruela-Arispe

. Notch signaling in vascular morphogenesis. Curr Opin Hematol 2004;11:278–83.

136.

Campos

Wang

Pollman

Gibbons

. Determinants of Notch-3 receptor expression and signaling in vascular smooth muscle cells: Implications in cell-cycle regulation. Circ Res 2002;91:999–1006.

137.

Domenga

Fardoux

Lacombe

Monet

Maciazek

Krebs

. Notch3 is required for arterial identity and maturation of vascular smooth muscle cells. Genes Dev 2004;18:2730–5.

138.

Proweller

Pear

Parmacek

. Notch signaling represses myocardininduced smooth muscle cell differentiation. J Biol Chem 2005;280:8994–9004.

139.

Zhang

Leathers

Makino

Huang

Parsa

. Notch3 signaling promotes the development of pulmonary arterial hypertension. Nat Med 2009;15:1289–97.

140.

Pasquinelli

Reinhart

Slack

Martindale

Kuroda

Maller

. Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature 2000;408:86–9.

141.

Filipowicz

Bhattacharyya

Sonenberg

. Mechanisms of posttranscriptional regulation by microRNAs: Are the answers in sight? Nat Rev Genet 2008;9:102–14.

142.

Humphreys

Westman

Martin

Preiss

. MicroRNAs control translation initiation by inhibiting eukaryotic initiation factor 4E/cap and poly(A) tail function. Proc Natl Acad Sci U S A 2005;102:16961–6.

143.

Meister

. miRNAs get an early start on translational silencing. Cell 2007;131:25–8.

144.

Olsen

Ambros

. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol 1999;216:671–80.

145.

Thermann

Hentze

. Drosophila miR2 induces pseudo-polysomes and inhibits translation initiation. Nature 2007;447:875–8.

146.

Thivierge

Flamand

Mathonnet

Vashisht

Wohlschlegel

. Pervasive and cooperative deadenylation of 3′UTRs by embryonic microRNA families. Mol Cell 2010;40:558–70.

147.

Sassen

Miska

Caldas

. MicroRNA: Implications for cancer. Virchows Arch 2008;452:1–10.

148.

Sonntag

Woo

Krichevsky

. Converging miRNA functions in diverse brain disorders: A case for miR-124 and miR-126. Exp Neurol 2012;235:427–35.

149.

Tomankova

Petrek

Kriegova

. Involvement of microRNAs in physiological and pathological processes in the lung. Respir Res 2010;11:159.

150.

Bentwich

Avniel

Karov

Aharonov

Gilad

Barad

. Identification of hundreds of conserved and nonconserved human microRNAs. Nat Genet 2005;37:766–70.

151.

Lee

Yang

Huang

Fan

Zhang

. Network modeling identifies molecular functions targeted by miR-204 to suppress head and neck tumor metastasis. PLoS Comput Biol 2010;6:e1000730.

152.

Bonnet

Michelakis

Porter

Andrade-Navarro

Thebaud

Bonnet

. An abnormal mitochondrial-hypoxia inducible factor-1 alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats-Similarities to human pulmonary arterial hypertension. Circulation 2006;113:2630–41.

153.

Paulin

Meloche

Jacob

Bisserier

Courboulin

Bonnet

. Dehydroepiandrosterone inhibits the Src/STAT3 constitutive activation in pulmonary arterial hypertension. Am J Physiol Heart Circ Physiol 2011;301:H1798–809.

154.

Humbert

Monti

Brenot

Sitbon

Portier

Grangeot-Keros

. Increased interleukin-1 and interleukin-6 serum concentrations in severe primary pulmonary hypertension. Am J Respir Crit Care Med 1995;151:1628–31.

155.

Brock

Trenkmann

Gay

Michel

Gay

Fischler

. Interleukin-6 modulates the expression of the bone morphogenic protein receptor type II through a novel STAT3-microRNA cluster 17/92 pathway. Cire Res 2009;104:1184–91.

156.

Ferracin

Veronese

Negrini

. Micromarkers: Mirnas in cancer diagnosis and prognosis. Expert Rev Mol Diagn 2010;10:297–308.

157.

Quintavalle

Elia

Condorelli

Courtneidge

. MicroRNA control of podosome formation in vascular smooth muscle cells in vivo and in vitro. J Cell Biol 2010;189:13–22.

158.

Cordes

Sheehy

White

Berry

Morton

Muth

. miR-145 and miR-143 regulate smooth muscle cell fate and plasticity. Nature 2009;460:705–10.

159.

Davis-Dusenbery

Chan

Reno

Weisman

Layne

Lagna

. Down-regulation of Kruppel-like factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-beta and bone morphogenetic protein 4. J Biol Chem 2011;286:28097–110.

160.

Caruso

Dempsie

Stevens

McDonald

Long

. A role for miR-145 in pulmonary arterial hypertension. Circ Res 2012;111:290–300.

161.

Bockmeyer

Maegel

Janciauskiene

Rische

Lehmann

Maus

. Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression. J Heart Lung Transplant 2012;31:764–72.

162.

Zhang

Luo

Ruan

Huang

Feng

. Identification of aberrantly expressed miRNAs in rectal cancer. Oncol Rep 2012;28:77–84.

163.

Meister

Schmidt

. miR-126 and miR-126*: New players in cancer. Scientific World Journal 2010;10:2090–100.

164.

Fish

Santoro

Morton

Yeh

Wythe

. miR-126 regulates angiogenic signaling and vascular integrity. Dev Cell 2008;15:272–84.

165.

Wang

Aurora

Johnson

McAnally

Hill

. The endothelial-specific microRNA miR-126 governs vascular integrity and angiogenesis. Dev Cell 2008;15:261–71.

166.

Meng

Cao

Zhang

Zhou

Shen

Wang

. Downregulation of microRNA-126 in endothelial progenitor cells from diabetes patients, impairs their functional properties, via target gene Spred-1. J Mol Cell Cardiol 2012;53:64–72.

167.

Zernecke

Bidzhekov

Noels

Shagdarsuren

Gan

Denecke

. Delivery of microRNA-126 by apoptotic bodies induces CXCL12-dependent vascular protection. Sci Signal 2009;2:ra81.

168.

Rhodes

Wharton

Boon

Roexe

Tsang

Wojciak-Stothard

. Reduced miR-150 is associated with poor survival in pulmonary arterial hypertension. Am J Respir Crit Care Med 2012;187:294–302.

169.

Bezman

Chakraborty

Bender

Lanier

. miR-150 regulates the development of NK and iNKT cells. J Exp Med 2011;208:2717–31.

170.

Xiao

Calado

Galler

Thai

Patterson

Wang

. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 2007;131:146–59.

171.

Zhang

Liu

Chen

Bian

. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 2010;39:133–44.

172.

Cheng

Yue

Yang

Liu

Chen

. MicroRNAs are aberrantly expressed in hypertrophic heart: Do they play a role in cardiac hypertrophy? Am J Pathol 2007;170:1831–40.

173.

Rolland-Turner

Goretti

Bousquenaud

Léonard

Nicolas

Zhang

. Adenosine stimulates the migration of human endothelial progenitor cells. Role of CXCR4 and MicroRNA-150. PLoS ONE 2013;8:e54135.

174.

Camps

Buffa

Colella

Moore

Sotiriou

Sheldon

. hsamiR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 2008;14:1340–8.

175.

Corn

. Hypoxic regulation of miR-210: Shrinking targets expand HIF-1's influence. Cancer Biol Ther 2008;7:265–7.

176.

Giannakakis

Sandaltzopoulos

Greshock

Liang

Huang

Hasegawa

. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 2008;7:255–64.

177.

Kulshreshtha

Davuluri

Calin

Ivan

. A microRNA component of the hypoxic response. Cell Death Differ 2008;15:667–71.

178.

Zhu

. MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 2007;282:14328–36.

179.

Zhu

Nie

Sheng

. MicroRNA-21 targets tumor suppressor genes in invasion and metastasis. Cell Res 2008;18:350–9.

180.

Guimbellot

Erickson

Mehta

Wen

Page

Sorscher

. Correlation of microRNA levels during hypoxia with predicted target mRNAs through genome-wide microarray analysis. BMC Med Genomics 2009;2:15.

181.

Hua

Wong

Cai

. MiRNA-directed regulation of VEGF and other angiogenic factors under hypoxia. PLoS ONE 2006;1:e116.

182.

Sarkar

Gou

Turaka

Viktorova

Ramchandran

Raj

. MicroRNA-21 plays a role in hypoxia-mediated pulmonary artery smooth muscle cell proliferation and migration. Am J Physiol Lung Cell Mol Physiol 2010;299:L861–71.

183.

Doebele

Bonauer

Fischer

Scholz

Reiss

Urbich

. Members of the microRNA-17-92 cluster exhibit a cell-intrinsic antiangiogenic function in endothelial cells. Blood 2010;115:4944–50.

184.

Pullamsetti

Doebele

Fischer

Savai

Kojonazarov

Dahal

. Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension. Am J Respir Crit Care Med 2012;185:409–19.

185.

Drake

Bogaard

Mizuno

Clifton

Xie

Gao

. Molecular signature of a right heart failure program in chronic severe pulmonary hypertension. Am J Respir Cell Mol Biol 2011;45:1239–47.

186.

Chen

Liang

Zhang

Zen

Zhang

. Horizontal transfer of microRNAs: Molecular mechanisms and clinical applications. Protein Cell 2012;3:28–37.

187.

Bhalla

Willis

Maisel

. B-Type natriuretic peptide: The level and the drug-partners in the diagnosis and management of congestive heart failure. Congest Heart Fail 2004;10(1 Suppl 1):3–27.

188.

Heresi

. Clinical perspective: Biomarkers in pulmonary arterial hypertension. Int J Clin Pract Suppl 2011;1:5–7.

189.

Di Stefano

Zaccagnini

Capogrossi

Martelli

. microRNAs as peripheral blood biomarkers of cardiovascular disease. Vascul Pharmacol 2011;55:111–8.

190.

Kong

Ferland-McCollough

Jackson

Bushell

. microRNAs in cancer management. Lancet Oncol 2012;13:e249–58.

191.

Renard

Paulin

Breuils-Bonnet

Simard

Pibarot

Bonnet

Provencher

. Pim-1: A new biomarker in pulmonary arterial hypertension. Pulm Circ. 2013;3:74–81.

192.

Galiè

Olschewski

Oudiz

Torres

Frost

Ghofrani

. Ambrisentan for the treatment of pulmonary arterial hypertension: Results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010–9.

193.

Kenyon

Nappi

. Bosentan for the treatment of pulmonary arterial hypertension. Ann Pharmacother 2003;37:1055–62.

194.

Iglarz

Binkert

Morrison

Fischli

Gatfield

Treiber

. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327:736–45.

195.

Bruderer

Hopfgartner

Seiberling

Wank

Sidharta

Treiber

. Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. Xenobiotica 2012;42:901–10.

196.

Barst

Rubin

Long

McGoon

Rich

Badesch

. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296–302.

197.

McLaughlin

Shillington

Rich

. Survival in primary pulmonary hypertension: The impact of epoprostenol therapy. Circulation 2002;106:1477–82.

198.

Simonneau

Barst

Galie

Naeije

Rich

Bourge

. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: A doubleblind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800–4.

199.

McLaughlin

Benza

Rubin

Channick

Voswinckel

Tapson

. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: A randomized controlled clinical trial. J Am Coll Cardiol 2010;55:1915–22.

200.

Olschewski

Simonneau

Galiè

Higenbottam

Naeije

Rubin

. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002;347:322–9.

201.

Simonneau

Torbicki

Hoeper

Delcroix

Karlócai

Galiè

. Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension. Eur Respir J 2012;40:874–80.

202.

Galiè

Brundage

Ghofrani

Oudiz

Simonneau

Safdar

. Tadalafil therapy for pulmonary arterial hypertension. Circulation 2009;119:2894–903.

203.

Ghofrani

Pepke-Zaba

Barbera

Channick

Keogh

Gomez-Sanchez

. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):68–72S.

204.

Kuschner

. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2006;354:1091–3.

205.

Jing

Shen

Zhu

. Vardenafil in pulmonary arterial hypertension: A randomized, double-blind, placebocontrolled study. Am J Respir Crit Care Med 2011;183:1723–9.

206.

Schermuly

Stasch

Pullamsetti

Middendorff

Müller

Schlüter

. Expression and function of soluble guanylate cyclase in pulmonary arterial hypertension. Eur Respir J 2008;32:881–91.

207.

Ghofrani

Hoeper

Halank

Meyer

Staehler

Behr

. Riociguat for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension: A phase II study. Eur Respir J 2010;36:792–9.

208.

Paulin

Courboulin

Barrier

Bonnet

. From oncoproteins/tumor suppressors to microRNAs, the newest therapeutic targets for pulmonary arterial hypertension. J Mol Med (Berl) 2011;89:1089–101.

209.

O'Callaghan

Savale

Montani

Jaïs

Sitbon

Simonneau

. Treatment of pulmonary arterial hypertension with targeted therapies. Nat Rev Cardiol 2011;8:526–38.

210.

Nakamura

Akagi

Ogawa

Kusano

Matsubara

Miura

. Pro-apoptotic effects of imatinib on PDGF-stimulated pulmonary artery smooth muscle cells from patients with idiopathic pulmonary arterial hypertension. Int J Cardiol 2011;159:100–6.

211.

Hoeper

Barst

Bourge

Feldman

Frost

Galiè

. Imatinib Mesylate as Add-on Therapy for Pulmonary Arterial Hypertension: Results of the Randomized IMPRES Study. Circulation 2013;127:1128–38.

212.

ten Freyhaus

Dumitrescu

Berghausen

Vantler

Caglayan

Rosenkranz

. Imatinib mesylate for the treatment of pulmonary arterial hypertension. Expert Opin Investig Drugs 2012;21:119–34.

213.

Gomberg-Maitland

Maitland

Barst

Sugeng

Coslet

Perrino

. A dosing/cross-development study of the multikinase inhibitor sorafenib in patients with pulmonary arterial hypertension. Clin Pharmacol Ther 2010;87:303–10.

214.

de la Roque

Dumas E

Savineau

Bonnet

. Dehydroepiandrosterone: A new treatment for vascular remodeling diseases including pulmonary arterial hypertension. Pharmacol Ther 2010;126:186–99.

215.

de la Roque

Dumas E

Savineau

Metivier

Billes

Kraemer

Doutreleau

. Dehydroepiandrosterone (DHEA) improves pulmonary hypertension in chronic obstructive pulmonary disease (COPD): A pilot study. Ann Endocrinol (Paris) 2012;73:20–5.

216.

Manu

Shanmugam

Rajendran

Ramachandran

Hay

. Plumbagin inhibits invasion and migration of breast and gastric cancer cells by downregulating the expression of chemokine receptor CXCR4. Mol Cancer 2011;10:107.

217.

Gomathinayagam

Sowmyalakshmi

Mardhatillah

Kumar

Akbarsha

Damodaran

. Anticancer mechanism of plumbagin, a natural compound, on non-small cell lung cancer cells. Anticancer Res 2008;28:785–92.

218.

Sandur

Pandey

Sung

Aggarwal

. 5-hydroxy-2-methyl-1, 4-naphthoquinone, a vitamin K3 analogue, suppresses STAT3 activation pathway through induction of protein tyrosine phosphatase, SHP-1: Potential role in chemosensitization. Mol Cancer Res 2010;8:107–18.

219.

Courboulin

Barrier

Perreault

Bonnet

Tremblay

Paulin

. Plumbagin reverses proliferation and resistance to apoptosis in experimental PAH. Eur Respir J 2012;40:618–29.

220.

Satoh

Kagaya

Nakano

Ito

Ohta

Tada

. Important role of endogenous erythropoietin system in recruitment of endothelial progenitor cells in hypoxia-induced pulmonary hypertension in mice. Circulation 2006;113:1442–50.

221.

Diller

van Eijl

Okonko

Howard

Ali

Thum

. Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension. Circulation 2008;117:3020–30.

222.

Junhui

Xingxiang

Guosheng

Yunpeng

Furong

Junzhu

. Reduced number and activity of circulating endothelial progenitor cells in patients with idiopathic pulmonary arterial hypertension. Respir Med 2008;102:1073–9.

223.

Asosingh

Aldred

Vasanji

Drazba

Sharp

Farver

. Circulating angiogenic precursors in idiopathic pulmonary arterial hypertension. Am J Pathol 2008;172:615–27.

224.

Toshner

Voswinckel

Southwood

Al-Lamki

Howard

Marchesan

. Evidence of dysfunction of endothelial progenitors in pulmonary arterial hypertension. Am J Respir Crit Care Med 2009; 180:780–7.

Signal Transduction in the Development of Pulmonary Arterial Hypertension

Abstract

Keywords

CLINICAL AND FUNDAMENTAL MANIFESTATIONS OF PAH

Abnormal pulmonary circulation

Abnormal right ventricular function

SIGNAL INITIATION: CIRCULATING FACTORS

Growth factors

Pro-inflammatory molecules

Vascular tone mediators imbalance

Ions imbalance

SIGNAL TRANSDUCTION: CRITICAL PATHWAYS THAT MAINTAIN AND AMPLIFY DISEASE PROGRESSION

Disrupted TGF-β signaling

The STAT3/NFAT pathway

Peroxisome proliferator-activated receptor γ

Notch signaling in PAH

MicroRNAs: FEED-FORWARD LOOP THAT CLOSES THE SYSTEM

CRITICAL LACK OF SPECIFIC BIOMARKERS IN PAH

CURRENT AND FUTURE TREATMENTS IN PAH

Improvement of current therapies in PAH

Future therapies in PAH

CONCLUSION AND FUTURE DIRECTION

Footnotes

References